These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Regimen-related toxicity following reduced-intensity stem-cell transplantation (RIST): comparison between Seattle criteria and National Cancer Center Common Toxicity Criteria (NCI-CTC) version 2.0. Sakiyama M; Kami M; Hori A; Imataki O; Hamaki T; Murashige N; Kobayashi K; Kishi Y; Kojima R; Kim SW; Kusumi E; Yuji K; Miyakoshi S; Mori S; Tanosaki R; Taniguchi S; Takaue Y; Bone Marrow Transplant; 2004 Nov; 34(9):787-94. PubMed ID: 15361909 [TBL] [Abstract][Full Text] [Related]
15. Comparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 years. Kojima R; Kami M; Kanda Y; Kusumi E; Kishi Y; Tanaka Y; Yoshioka S; Morishima S; Fujisawa S; Mori SI; Kasai M; Hatanaka K; Tajima K; Kasai M; Mitani K; Ichinohe T; Hirai H; Taniguchi S; Sakamaki H; Harada M; Takaue Y Bone Marrow Transplant; 2005 Oct; 36(8):667-74. PubMed ID: 16113674 [TBL] [Abstract][Full Text] [Related]
16. Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia. Zhao Y; Wang J; Luo Y; Shi J; Zheng W; Tan Y; Cai Z; Huang H Ann Hematol; 2017 Aug; 96(8):1353-1360. PubMed ID: 28624905 [TBL] [Abstract][Full Text] [Related]
17. Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution. Nakai K; Mineishi S; Kami M; Saito T; Hori A; Kojima R; Imataki O; Hamaki T; Yoshihara S; Ohnishi M; Kim SW; Ando T; Fumitoh A; Kanda Y; Makimoto A; Tanosaki R; Kanai S; Heike Y; Ohnishi T; Kawano Y; Wakasugi H; Takaue Y Transplantation; 2003 Jun; 75(12):2135-43. PubMed ID: 12829926 [TBL] [Abstract][Full Text] [Related]
18. Dose-surface analysis for prediction of severe acute radio-induced skin toxicity in breast cancer patients. Pastore F; Conson M; D'Avino V; Palma G; Liuzzi R; Solla R; Farella A; Salvatore M; Cella L; Pacelli R Acta Oncol; 2016; 55(4):466-73. PubMed ID: 26623532 [TBL] [Abstract][Full Text] [Related]
19. RIST: a potent new combination therapy for glioblastoma. Nonnenmacher L; Westhoff MA; Fulda S; Karpel-Massler G; Halatsch ME; Engelke J; Simmet T; Corbacioglu S; Debatin KM Int J Cancer; 2015 Feb; 136(4):E173-87. PubMed ID: 25123598 [TBL] [Abstract][Full Text] [Related]
20. Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation. Saito T; Kanda Y; Nakai K; Kim SW; Arima F; Kami M; Tanosaki R; Tobinai K; Wakasugi H; Heike Y; Mineishi S; Takaue Y Bone Marrow Transplant; 2003 Sep; 32(6):601-8. PubMed ID: 12953133 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]